Last updated on October 2018

An Investigational Immuno-therapy Study of Nivolumab or Placebo in Patients With Resected Esophageal or Gastroesophageal Junction Cancer

Brief description of study

The purpose of this study is to determine whether Nivolumab will improve overall survival, disease-free survival, or both compared with placebo.

Clinical Study Identifier: NCT02743494

Contact Investigators or Research Sites near you

Start Over

Crystal Denlinger, Site 0048

Fox Chase Cancer Center
Philadelphia, PA United States
  Connect »